Recombinant antigen-based lateral flow tests for the detection of Strongyloides stercoralis infection
PLOS Neglected Tropical Diseases · 08.04.2025 · 19 (4) · e0013018
DOI: 10.1371/journal.pntd.0013018 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 08.04.2025. Verfasst von Robertine Lontuo-Fogang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Parasitic Diseases, NIAID, National Institutes of Health, Bethesda, Maryland, United States of America. Hauptthemen laut MEDLINE: Strongyloidiasis, Strongyloides stercoralis, Antigens, Helminth, Antibodies, Helminth. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Intramural NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Strongyloidiasis is a serious public health issue affecting millions of people worldwide particularly in tropical and subtropical regions. The laboratory diagnosis of strongyloidiasis is often serologically based, typically by enzyme linked immunosorbent assays (ELISA). However, the use of these assays at the point of care requires significantly different approaches for serologic measurements. We sought to determine the diagnostic performance of 2 prototype lateral flow tests alongside the Strongy Detect ELISAs (IgG and IgG4) that uses a cocktail of 2 Ss-specific recombinant antigens, Ss-NIE and Ss-IR.
Methods
The diagnostic performance of the Rapid Diagnostic Tests (RDTs) and ELISAs was determined by using stored serum samples from 17 healthy volunteers, 77 individuals known to be stool positive for Strongyloides stercoralis (Ss) , 44 Ss stool-negative individuals but positive for Loa loa (n=32 ), or other helminths (n=12) (hookworm infection, Schistosoma mansoni , or Wuchereria bancrofti) . Concordance between the RDTs and ELISAs was calculated with the Cohen’s kappa statistic (κ).
Results
The sensitivity and specificity of the IgG RDT was 95% (95% CI; 87.84 to 98.64%) and 94% (95% CI; 84.99 to 98.30%) respectively. The IgG4 RDT showed a sensitivity of 86.5% (95% CI; 77.63 to 92.83%) with 100% (95% CI; 94.13 to 100%) specificity. The IgG-based ELISA showed 100% (95% CI; 95.6-100%) sensitivity and 96% specificity (95% CI; 91.7-98%), whereas the IgG4-based ELISA revealed a 90% (95% CI; 81-94.3%) sensitivity with 100% (95% CI; 97.8-100%) specificity. Concordance between the RDTs and the ELISAs was excellent with κ = 0.94 (95% CI; 0.88-1.0%) for the IgGs and κ = 0.89 (95% CI; 0.81-0.97%) for IgG4 assays.
Conclusion
Given the high degree of sensitivity and specificity of both the IgG- and IgG4-based RDT, either of these would be useful in assessing Ss seropositivity in population-based studies and in screening patients at the point of contact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Parasitic Diseases, NIAID, National Institutes of Health, Bethesda, Maryland, United States of America.
ORCID-Profile: Robertine Lontuo-Fogang
Förderung
- Intramural NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Zitieren
APA
Lontuo-Fogang, R., & Nutman, T. B. (2025). Recombinant antigen-based lateral flow tests for the detection of Strongyloides stercoralis infection. PLOS Neglected Tropical Diseases, 19(4), e0013018. https://doi.org/10.1371/journal.pntd.0013018
Vancouver
Lontuo-Fogang R, Nutman TB. Recombinant antigen-based lateral flow tests for the detection of Strongyloides stercoralis infection. PLOS Neglected Tropical Diseases. 2025;19(4):e0013018. doi:10.1371/journal.pntd.0013018
BibTeX
@article{LontuoFogang2025,
author = {Lontuo-Fogang, Robertine and Nutman, Thomas B},
title = {Recombinant antigen-based lateral flow tests for the detection of Strongyloides stercoralis infection},
journal = {PLOS Neglected Tropical Diseases},
year = {2025},
volume = {19},
number = {4},
pages = {e0013018},
doi = {10.1371/journal.pntd.0013018}
}
EUVIMED